Our glycemic balance is based on the ability of the pancreatic beta cells to detect glucose and secrete insulin to maintain our blood sugar levels. If these cells malfunction, the balance is broken, ...

Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...

Following a low-carb diet may potentially help patients manage disease more effectively and reduce medication use. Study: Effects of a Carbohydrate-Restricted Diet on β-Cell Response in Adults With ...

A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), Leonardo Ferreira, Ph.D., is taking on type 1 diabetes (T1D) with support ...

Biomea Fusion, Inc. has presented promising clinical results for icovamenib, a novel therapy aimed at restoring beta-cell function in patients with type 2 diabetes, at the ATTD 2025 Conference.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A restricted ...

Please provide your email address to receive an email when new articles are posted on . Greater weight loss at 1 year with tirzepatide improved the odds for sustaining an HbA1c of 6.5% or less at 2 ...

In 2021, a research team discovered the insulin-inhibitory receptor 'Inceptor' and its role as a suppressor of the insulin signaling pathway. Now, the researchers have unlocked another, even more ...

In recent years, we have come to appreciate that loss or dysfunction of insulin-producing islet beta cells underlies virtually all major forms of diabetes mellitus. In type 1 diabetes, beta cells ...

More than 38 million Americans have diabetes, and more than 90 percent of them have Type 2 diabetes. Type 2 diabetes usually presents in people who are 45 or older. However, it is becoming more common ...